ProQR Therapeutics N.V.
PRQR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612940
In the last 90 days, ProQR Therapeutics N.V. insiders filed 4 open-market purchases and 0 sales; 70 institutions reported holding it in 13F filings for Q2 2026, worth $113.0M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding ProQR Therapeutics N.V. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 46 | 47 | +1 |
| Shares | 18.7M | 18.4M | −324.8K (−1.7%) |
| Value | $24.3M | $37.0M | +$12.6M (+51.9%) |
New holders (6)
Institutions that held ProQR Therapeutics N.V. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deutsche Bank AG | 385,208 | $762.7K | 0.00% |
| Citadel Advisors LLC | 77,816 | $154.1K | 0.00% |
| Virtu Financial LLC | 34,904 | $69.0K | 0.01% |
| Bank of Montreal | 30,000 | $66.3K | 0.00% |
| Two Sigma Securities, LLC | 10,637 | $21.1K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,536 | $7.00K | 0.00% |
Sold out (5)
Institutions that held ProQR Therapeutics N.V. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| UBS Oconnor LLC | 189,328 | $246.1K |
| Gsa Capital Partners LLP | 74,084 | $96.0K |
| Invesco Ltd. | 20,822 | $27.1K |
| Flaharty Asset Management, LLC | 2,000 | $2.60K |
| Geneos Wealth Management Inc. | 1,000 | $1.30K |